Fenofibrate for Prevention of Diabetic Retinopathy Worsening(Protocol AF)
A multi-center study being conducted by DRCR Retina Network sponsored by the National Institutes of Health, the U.S. Department of Health and Human Services. Your eye doctor is taking part in a study to find out if a pill taken by mouth can slow or prevent worsening of a condition called diabetic retinopathy. This study is being done by the DRCR Retina Network. The Network is a group of clinical sites dedicated to research of retinal diseases. It includes over 100 eye clinics in the United States and Canada. The Network started over 15 years ago and has run over 30 studies on retinal disease.
If you are interested in learning more, please contact Marybeth Carter at Marybeth.L.Carter@vumc.org or 615-936-1639
CLICK HERE to learn more
Understanding Retinal Vascular Changes during Pregnancy and the Impact on Maternal and Fetal Health
The goal of this study is to better understand how the back part of the eye—called the retina and the choroid—changes during pregnancy. We will take specialized photos of the eye at three different timepoints: early in pregnancy (first or second trimester), late in pregnancy (third trimester), and after you deliver. This imaging is non-invasive and does not require contact with the surface of the eye. The patient simply rests their chin on a machine that resembles a slit lamp, which is the tabletop microscope used in the eye clinic. The photos taken will allow us to assess specific parameters, like blood flow and the health of specialized cells that support vision. Understanding how the eyes change during pregnancy may help guide how retina specialists counsel their patients and how frequently they see them.
If you are interested in learning more, please email Havin Abdulkadir at havin.e.abdulkadir@vumc.org
The Galaxy Study
Principal Investigator, Avni Finn, MD and Study Coordinator, Alaina Stump are collaborating on a new clinical trial with ONL Therapeutics. The GALAXY study is evaluating a new study drug (ONL1204) to fi nd out how safe and how e ective it is for those with geographic atrophy (GA) due to AMD. Please contact Alaina Stumpf at Alaina.stumpf@vumc.org or (615)322-8920 if you are interested in learning more.
The Sienna Study
Principal Investigator Hadi Kaakour, MD and Study Coordinator Alaina Stumpf, are participating in a new clinical trial with Regeneron Pharmaceuticals to investigate systemic complement inhibition via subcutaneous administration in participants with Geographic Atrophy (GA) secondary to Age Related Macular Degeneration (AMD). The study will be using subcutaneous injections of pozelimab + cemdisiran combination therapy and cemdisiran monotherapy versus placebo. Please contact Alaina Stumpf at Alaina.stumpf@vumc.org or (615)322-8920 if you are interested in learning more.